Description
Overview
Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH). Researchers study its effects on growth-hormone signalling, IGF-1 activity and the distribution of abdominal fat.
Potential Benefits — Research Is Ongoing
Human benefits have mainly been studied in adults with HIV-associated excess abdominal fat; they cannot be assumed for healthy adults or this B&A presentation.
- Visceral-fat reduction: May help reduce deep abdominal fat surrounding internal organs.
- Waist and abdominal-profile improvement: May support reductions in abdominal fat accumulation.
- Liver-fat reduction: May reduce excess liver fat in studied adults with HIV and fatty liver.
- Lipid-profile improvement: May improve selected blood-fat measures in the populations studied.
- Growth-hormone signalling: May stimulate the body’s own growth-hormone and IGF-1 pathways.
Research sources: Tesamorelin visceral-fat trial; HIV fatty-liver trial.
Research Overview
The strongest human evidence concerns adults living with HIV who have excess abdominal fat associated with lipodystrophy. Findings from these clinical populations cannot automatically be applied to healthy adults or to this B&A research product.
Mechanism / Pathway
Tesamorelin activates GHRH receptors in the pituitary, stimulating the release of the body’s own growth hormone and increasing circulating IGF-1. Researchers examine how this pathway influences fat metabolism and body composition. An increase in these hormones is a biological effect, not automatically a health benefit. [3]
Important Research Information
Approved tesamorelin medicines have a specific indication for excess abdominal fat in adults with HIV-associated lipodystrophy; that approval does not apply to this B&A pen. Tesamorelin is not indicated for general weight-loss management. Claims of muscle building, improved recovery or anti-ageing benefits in healthy adults are not established by the cited evidence.
Clinical prescribing information identifies risks including raised IGF-1, glucose intolerance or diabetes, fluid retention, joint discomfort and hypersensitivity. Long-term cardiovascular safety has not been established. [3]
Published Research
- Falutz et al. (2010): Randomised trial of tesamorelin in HIV-associated abdominal fat accumulation.
- Stanley et al. (2014): Randomised clinical trial examining visceral fat and liver fat.
- EGRIFTA WR prescribing information: indication, mechanism, limitations and safety.
Scientific Profile
- Identity: Tesamorelin
- Structural class: Synthetic growth-hormone-releasing hormone analogue
- Pathway: Pituitary GHRH-receptor activity and downstream GH/IGF-1 signalling
- Evidence population: Much of the cited clinical evidence concerns HIV-associated excess abdominal fat, not general bodybuilding
Research Areas
- GH/IGF-1 signalling
- Visceral and liver-fat outcomes in selected clinical populations
- Glucose tolerance, fluid retention and long-term safety questions
Product Presentation & Storage
- Format: 3 mL prefilled disposable research pen
- Pen graduation: 300 clicks
- Research compound: Tesamorelin 2 mg
- Storage: Keep refrigerated at 2–8°C and protect from light
Research-Use Notice
Tesamorelin 2 mg product guide
Check the Tesamorelin 2 mg product guide for supporting identification and research information alongside this pen listing. The total labelled amount does not replace batch-specific volume, concentration or expiry details.
Browse the Performance & Body Composition collection to compare complete product names and ingredient amounts. Single-product and blended listings have different contents.
For a related listing, compare the CJC 5 mg + Ipamorelin 5 mg + Tesamorelin 2 mg pen. It is a separate three-ingredient listing. Compare the full labelled contents.
Warnings, Contraindications & Safety Information
Research use only. This is an evidence-limited safety summary, not a package insert, complete prescribing information or permission for self-administration. References to licensed medicines describe those specific products; they do not establish B&A product approval, equivalence or safety.
Contraindications & Who Should Avoid Exposure
Licensed tesamorelin medicines list pregnancy, active malignancy, certain disruptions of the hypothalamic-pituitary axis and ingredient hypersensitivity as contraindications. These are reference-medicine restrictions, not a validated suitability assessment for this research presentation.
Warnings & Precautions
Licensed tesamorelin prescribing information warns about raised IGF-1, glucose intolerance or diabetes, fluid retention and hypersensitivity. Those medicine-specific instructions do not establish safety or equivalence for this B&A research pen. Pregnancy, breastfeeding and use in children require particular caution; this is not a human-use product.
Possible Adverse Reactions
Medicine-label reports include fluid retention, joint or muscle discomfort, local reactions and hypersensitivity. Reaction frequencies and long-term outcomes cannot be assumed for this pen.
Drug & Supplement Interactions
Drug and supplement interactions have not been adequately characterised for this presentation. Do not assume that combining it with prescription medicines, hormones or other research compounds is safe. Give a clinician the full ingredient list if exposure has occurred.
When to Seek Urgent Help
Seek emergency care for difficulty breathing, swelling of the face or throat, collapse, severe persistent abdominal pain, or repeated vomiting with inability to keep fluids down. Stop further exposure and show the clinician the product label and ingredient list.
Handling & Storage Cautions
Follow the actual product label and batch-specific expiry information. Do not use damaged, contaminated or unexpectedly changed material. A clear appearance, refrigeration or addition of bacteriostatic water does not prove sterility, compatibility or a safe shelf life. Do not share needles, pens or opened material between people.
Safety references: Tesamorelin medicine prescribing information. Information reviewed 25 October 2026.
Reviews
There are no reviews yet.